AlphAIalphai — Financial news for AI agents
MarketBeatAPR 183 min read$RPID

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Sees Large Increase in Short Interest

Rapid Micro Biosystems (NASDAQ:RPID) experienced an 18.9% increase in short interest, reaching 377,502 shares as of March 31st, indicating a 1.4 days-to-cover ratio. This occurred despite recent insider selling by the COO and CFO, who disposed of shares worth over $73,000 in March. The company also reported missing EPS estimates but exceeded revenue expectations for the last quarter, with a current market capitalization of approximately $103.7 million.

Original reporting
MarketBeat · MarketBeat
Published Apr 18, 2026, 10:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 18, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Sees Large Increase in Short Interest — source image
Source · MarketBeat
Decision brief

The 30-second read

$RPIDBearishMed
01

Why it matters

The combination of insider activity and rising short interest suggests increased caution among traders, possibly leading to short-term downward pressure.

02

Market read

The news is relevant for traders focusing on biotech stocks, especially those with short-term trading strategies.

03

What to watch

Potential upcoming catalysts or sector-wide recovery could offset current bearish signals.

Timing: short-term

Background

Rapid Micro Biosystems recently reported mixed earnings and experienced insider selling, alongside a notable increase in short interest, signaling potential bearish sentiment.

Company-level read

Ticker impact

$RPIDBearishMedium confidence
Context

The news about increased short interest and insider selling may impact RPID's stock price.

Expected impact

Potential short-term decline or increased volatility due to bearish sentiment and insider selling, with a possible rebound if fundamentals improve.

Evidence & confidence

The rise in short interest suggests traders are betting against the stock, but the mixed earnings and insider activity present a complex picture. Technical indicators and broader market conditions should be monitored for confirmation.

Market effects

Sector

The biotech and life sciences sector may see increased scrutiny or volatility due to company-specific news.

Regional

Limited regional impact; primarily affects NASDAQ-listed biotech stocks.

Global

Low; company-specific news unlikely to influence global markets.

Counterpoint

What could challenge this read

The insider selling might be routine and not indicative of future performance; the earnings miss could be temporary.

Key entities

  • Company
    Rapid Micro Biosystems

    A biotech company specializing in microbiology automation.

Read at source← All news

Related articles

AUG 14
$RPIDMedAI 8/10

Rapid Micro Biosystems (RPID) Q2 2026 Earnings Call Transcript

Rapid Micro Biosystems (RPID) reported Q2 2026 revenue of $8.1M, up 10.9% YoY, with product revenue $5.3M and service revenue $2.8M. Recurring revenue was $5.0M, up 14.3% YoY, and gross margin was 15.0%. Net loss was $12.9M ($0.27/share). Full-year revenue guidance was reaffirmed at $37M to $41M.

fool.com6 min
AUG 9
MedAI 8/10

Rapid Micro Biosystems, Inc. Q2 2026 Earnings Call Summary

Rapid Micro Biosystems reported record Q2 2026 consumable revenue and units, supporting a 15% record gross margin. Full-year validation guidance was raised to at least 27 systems. Q2 adjusted EBITDA loss was $10.3 million. Management expects mid-to-high 20% Q4 gross margins, a $3 million annual expense reduction starting 2027, and expanded MilliporeSigma-driven placements in 2H 2026.

yahoo.com7 min
AUG 7
$RPIDMed

Rapid Micro Biosystems Q2 Earnings Call Highlights

Rapid Micro Biosystems (NASDAQ: RPID) reported Q2 margin improvements, with consumables margins up 17 points YoY and service margin at a record 49%. Operating expenses rose to $13.5M. Net loss was $12.9M ($0.27/share). The company reaffirmed 2026 revenue guidance of $37M-$41M, raised validation targets, and projected Q3 revenue at least $9.5M.

yahoo.com4 min
AUG 7
$RPIDMedAI 8/10

Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results

Rapid Micro Biosystems (Nasdaq: RPID) reported Q2 2026 total revenue of $8.1 million, up 11% year over year. Recurring revenue rose 14% to $5.0 million, 63% of total. Gross margin was a record 15%. The company reaffirmed 2026 revenue guidance of $37.0 million to $41.0 million and gross margin near 20%, and raised validation guidance to at least 27.

finanznachrichten.de7 min
AUG 7
$RPIDMed

RAPID MICRO BIOSYSTEMS, INC. (RPID): Results of Operations and Financial Condition

RAPID MICRO BIOSYSTEMS, INC. (RPID) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results • Reports second quarter 2026 total revenue of $8.1 million, representing 11% growth compared to the second quarter of 2025 ◦ Achieved a significant milestone with the 200th Growth Direct system pla

SEC EDGAR 8-K6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min